Pioglitazone inhibits oxidative stress, MMP-mediated inflammation and vascular dysfunction in high glucose-induced human saphenous vein grafts

Onursal, Ceylan; Reel, Buket; Bintepe, Caglar; Guzeloglu, Mehmet; Ersoy, Nevin; Bağrıyanık, Alper

doi:10.1016/j.jdiacomp.2023.108421

Cited by 5 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the pathophysiological mechanism of AD has not been fully explained. Chronic hyperglycemic conditions are known to enhance the elevation of MMP-13 protein expression in neuronal tissue, which causes neurovascular damage [ 35 , 36 ]. The inhibition of MMP-13 by natural carotenoids attenuates diabetic neurovascular damage and cognitive dysfunction [ 35 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

Astaxanthin: A Marine Drug That Ameliorates Cerebrovascular-Damage-Associated Alzheimer’s Disease in a Zebrafish Model via the Inhibition of Matrix Metalloprotease-13

Paramakrishnan,

Lim,

Paramaswaran

et al. 2023

Marine Drugs

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a major type of dementia disorder. Common cognitive changes occur as a result of cerebrovascular damage (CVD) via the disruption of matrix metalloproteinase-13 (MMP-13). In diabetic cases, the progress of vascular dementia is faster and the AD rate is higher. Patients with type 2 diabetes are known to have a higher risk of the factor for AD progression. Hence, this study is designed to investigate the role of astaxanthin (AST) in CVD-associated AD in zebrafish via the inhibition of MMP-13 activity. CVD was developed through the intraperitoneal and intracerebral injection of streptozotocin (STZ). The AST (10 and 20 mg/L), donepezil (1 mg/L), and MMP-13 inhibitor (i.e., CL-82198; 10 μM) were exposed for 21 consecutive days in CVD animals. The cognitive changes in zebrafish were evaluated through light and dark chamber tests, a color recognition test, and a T-maze test. The biomarkers of AD pathology were assessed via the estimation of the cerebral extravasation of Evans blue, tissue nitrite, amyloid beta-peptide aggregation, MMP-13 activity, and acetylcholinesterase activity. The results revealed that exposure to AST leads to ameliorative behavioral and biochemical changes. Hence, AST can be used for the management of AD due to its multi-targeted actions, including MMP-13 inhibition.

show abstract